In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Trelegy is aimed at patients who require treatment with three drugs to keep their symptoms in check, allowing them to take their medicine in a daily dose in a single inhaler, rather than using ...

European regulators have refused to back GlaxoSmithKline’s daily triple therapy Trelegy Ellipta for asthma ... thanks to its ageing asthma and COPD inhaler Advair, which finally succumbed ...